<DOC>
	<DOC>NCT02890173</DOC>
	<brief_summary>To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.</brief_summary>
	<brief_title>Study of CS-3150 in Patients With Essential Hypertension</brief_title>
	<detailed_description>Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg compared to Eplerenone in patients with essential hypertension. Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg compared to 2.5 mg.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Male and female subjects aged 20 years or older at informed consent Subjects with essential hypertension satisfying the following blood pressure criteria; Sitting SBP: ≥ 140 mmHg and &lt; 180 mmHg Sitting DBP: ≥ 90 mmHg and &lt; 110 mmHg Mean 24 hr BP: SBP ≥ 130 and DBP ≥ 80 mmHg Secondary hypertension or malignant hypertension Diabetic nephropathy or diabetes mellitus with albuminuria Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L Reversed daynight life cycle including overnight workers eGFR &lt; 60 mL/min/1.73 m^2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
	<keyword>Esaxerenone</keyword>
	<keyword>Ambulatory blood pressure monitoring</keyword>
</DOC>